Sabby Management’s Decoy Therapeutics DCOY Stock Holding History

Sabby Management’s Portfolio DCOY Stock Details DCOY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-7	Closed	-$264K	–	200
2021 Q2	$264K	Hold	7	–	–	0.04%	123
2021 Q1	$395K	Buy	+7	New	+$401K	0.08%	118

Other funds holding DCOY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

XSC

X-Square Capital Guaynabo, Puerto Rico $394M AUM 44.75% 1-Year Est. Return

Sabby Management's DCOY Position: Q3 2021 in Review

Sabby Management sold out of Decoy Therapeutics (DCOY) in Q3 2021, closing a stake of 7 shares — an estimated $264K sold.

Sabby Management first reported a position in DCOY in Q1 2021 and held it in 2 quarters. The position peaked at $395K in Q1 2021. 20 funds tracked by Wall St. Rank hold DCOY as of Q3 2021.

Sabby Management reported no remaining Decoy Therapeutics position as of Q3 2021 after selling out during the quarter.
Sabby Management sold 7 Decoy Therapeutics shares in Q3 2021, an estimated $264K.
Sabby Management first reported a position in Decoy Therapeutics in Q1 2021 and held it in 2 quarters.
Sabby Management's Decoy Therapeutics position peaked at $395K in Q1 2021.
20 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q3 2021.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.